^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ACTA2 overexpression

    i
    Other names: ACTA2, Actin Alpha 2 Smooth Muscle, ACTSA, Cell Growth-Inhibiting Gene 46 Protein, Actin Alpha 2 Smooth Muscle Aorta, Actin Aortic Smooth Muscle, Alpha-Cardiac Actin, Alpha-Actin-2, ACTA2, ACTVS
    Entrez ID:
    59
    Related biomarkers:
    Expression
    Others
    1year
    Deep learning and transfer learning identify breast cancer survival subtypes from single-cell imaging data. (PubMed, Commun Med (Lond))
    This work provides an approach to bridge single-cell level information toward population-level survival prediction.
    Journal • BRCA Biomarker
    |
    BRCA (Breast cancer early onset) • CDH1 (Cadherin 1) • ACTA2 (Actin Alpha 2 Smooth Muscle) • GATA3 (GATA binding protein 3)
    |
    ACTA2 overexpression • CDH1 expression • CDH1 overexpression
    over1year
    Long Noncoding RNA ACTA2-AS1 Inhibits Cell Growth and Facilitates Apoptosis in Gastric Cancer by Binding with miR-6720-5p to Regulate ESRRB. (PubMed, Biochem Genet)
    Furthermore, ESRRB knockdown reversed the influence of ACTA2-AS1 overexpression on GC proliferation and apoptosis. ACTA2-AS1 plays an antioncogenic role in GC via binding with miR-6720-5p to regulate ESRRB expression.
    Journal
    |
    ACTA2 overexpression • ACTA2 elevation
    2years
    ACTA2 expression predicts survival and is associated with response to immune checkpoint inhibitors in gastric cancer. (PubMed, Clin Cancer Res)
    ACTA2 expression is associated with survival and ICI response in gastric cancer patients. ACTA2 expression in cancer-associated fibroblasts, but not in other cellular compartments, appears to be associated with ICI response.
    Journal • Checkpoint inhibition • MSi-H Biomarker • IO biomarker
    |
    MSI (Microsatellite instability) • ACTA2 (Actin Alpha 2 Smooth Muscle)
    |
    MSI-H/dMMR • ACTA2 overexpression • ACTA2 underexpression
    over2years
    lncRNA ACTA2-AS1 predicts malignancy and poor prognosis of triple-negative breast cancer and regulates tumor progression via modulating miR-532-5p. (PubMed, BMC Mol Cell Biol)
    ACTA2-AS1 and miR-532-5p could act as biomarkers of TNBC predicting the progression and prognosis of patients. ACTA2-AS1 served as a tumor suppressor of TNBC which was mediated by miR-532-5p.
    Journal
    |
    ACTA2 (Actin Alpha 2 Smooth Muscle) • MIR532 (MicroRNA 532)
    |
    ACTA2 overexpression
    over2years
    Overexpression of long non-coding RNA ACTA2-AS1 inhibits the viability, proliferation, migration and invasion of colorectal cancer cells. (PubMed, Tissue Cell)
    ACTA2-AS1 silencing, however, did oppositely. Collectively, ACTA2-AS1 inhibits the viability, proliferation, migration and invasion of CRC cells to effectively suppress the progression of CRC.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • ACTA2 (Actin Alpha 2 Smooth Muscle) • MMP2 (Matrix metallopeptidase 2) • CASP3 (Caspase 3) • MMP9 (Matrix metallopeptidase 9) • PCNA (Proliferating cell nuclear antigen)
    |
    BCL2 expression • ACTA2 overexpression • PCNA expression
    almost3years
    lncRNA ACTA2-AS1 inhibits malignant phenotypes of gastric cancer cells. (PubMed, Open Med (Wars))
    Moreover, PLCXD2 knockdown rescued the inhibitory effect of ACTA2-AS1 overexpression on malignant behaviors of GC cells. Overall, ACTA2-AS1 inhibits malignant phenotypes of GC cells by acting as a ceRNA to target miR-378a-3p/PLCXD2 axis.
    Journal
    |
    ACTA2 (Actin Alpha 2 Smooth Muscle)
    |
    ACTA2 overexpression